Medical Condition News

RSS

Researchers estimate increasing trend of hyperuricemia among adults, senior citizens

Hyperuricemia rates among the nation's adults and senior citizens remain substantially high, putting them at greater risk for developing gout, according to research presented at the Nov 2010, American College of Rheumatology Annual Scientific Meeting in Atlanta.

10 Nov 2010

Families fight to care for disabled kids at home after they reach the age of 21

NPR reports on families who are fighting for continued funding to care for their severely disabled children at home.

10 Nov 2010

ECRI Institute introduces CT Radiation Dose Safety Review service to reduce risk of excessive radiation

Keeping radiation dose in check is a top safety concern for today's hospitals, particularly in computed tomography, which has undergone some significant technological advances in the last ten years. The down side is that CT delivers some of the highest radiation doses in diagnostic radiology.

10 Nov 2010

Synageva's SBC-102 enzyme replacement therapy for LAL deficiency granted European orphan product designation

Synageva BioPharma Corp., a privately held biopharmaceutical company, announced that the European Medicines Agency (EMA) granted orphan product designation for SBC-102 (Recombinant Human Lysosomal Acid Lipase), the Company's enzyme replacement therapy in development to treat Lysosomal Acid Lipase (LAL) Deficiency.

10 Nov 2010

Neogenix awarded $488,958.50 grant under QTDP program

Neogenix Oncology, Inc. announced today that the company has been awarded two grants totaling $488,958.50, under the Qualifying Therapeutic Discovery Project Program. The two successful applications were for the company's h16C3 therapeutic antibody development program and the diagnostic biomarker development program for both their h16C3 and NPC-1C antibodies.

10 Nov 2010

Clot-busting drug remains the most beneficial emergency treatment for strokes

The clot-busting drug rt-PA remains the most beneficial proven emergency treatment for strokes caused by blood clots, according to an editorial in the November issue of Archives of Neurology by Dr. Jos- Biller.

10 Nov 2010

Special Surgery investigators to present future of clinical care at ACR annual meeting

Hospital for Special Surgery physicians who focus on lupus, scleroderma and related conditions are traveling from New York City to Atlanta this week to share their recent findings at the 74th Annual Scientific Meeting of the American College of Rheumatology (ACR).

10 Nov 2010

New robotic surgery technique for kidney cancer reduces organ damage

A new method of surgery for kidney cancer could help reduce organ damage, leading to more successful treatment of the disease, scientists have discovered.

10 Nov 2010

BioInvent receives FDA IND clearance for BI-204 Phase II trial in cardiovascular disease

BioInvent International AB today announces IND clearance from the U.S. Food & Drug Administration (FDA) to initiate a Phase II study for BI-204. BI-204 is a human monoclonal antibody that specifically targets oxidized forms of a low-density lipoprotein (LDL) which has been linked to increased inflammatory processes leading to plaque formation in the blood vessel walls. BI-204 is being co-developed with Genentech for secondary prevention of cardiovascular events in patients with acute coronary syndrome (ACS).

10 Nov 2010

Immunologix partners with Genscript to develop human antibody therapeutics

Immunologix, Inc, a Charleston, SC biotechnology company and a leader in fully human therapeutic antibodies for a variety of diseases and GenScript, a contract research organization (CRO) based in Piscataway, NJ and the industry leader in bio-reagent services, assay development & screening, lead optimization, and antibody drug development, announced today that the companies have formed a strategic partnership to offer a complete platform for producing human antibody therapeutics.

10 Nov 2010

Restylane boosts people's first impression

A recent study demonstrating that the treatment of nasolabial folds with Restylane positively influences the first impression that an individual projects was published by Dr. Steven Dayan (www.drdayan.com) and DeNova research in the November 2010 issue of Dermatologic Surgery, a leading Dermatology journal. In a study 20 patients received Restylane the popular hyaluronic filler to fill in the nasolabial folds which run from the side of the nose to the side of the mouth.

10 Nov 2010

Adolescent obesity associated with risk of severe obesity in adulthood

Obese adolescents are 16 times more likely to become severely obese by age 30 than their healthy weight or even overweight peers, according to a new study from the University of North Carolina at Chapel Hill.

10 Nov 2010

TONIX Pharmaceuticals announces Phase 2a study results of cyclobenzaprine in Fibromyalgia Syndrome

TONIX Pharmaceuticals (formerly known as Krele Pharmaceuticals), a specialty central nervous system (CNS) pharmaceutical company, announced results of a new analysis of a Phase 2a study, which previously demonstrated reduced pain, fatigue and tenderness in patients with Fibromyalgia Syndrome (FMS) following bedtime administration of very low dosage (VLD) cyclobenzaprine (CBP).

10 Nov 2010

Silence Therapeutics' Atu027 RNAi drug prevents pulmonary metastasis formation

Silence Therapeutics plc announces positive research findings demonstrating the ability of the Company's lead RNA interference (RNAi) drug candidate, Atu027, to prevent the formation of pulmonary metastasis in various animal models of cancer metastasis. Researchers showed that Atu027 inhibited multiple key biological processes that enable and contribute to the dissemination and formation of pulmonary metastases in a murine breast cancer metastasis model.

10 Nov 2010

Diamyd completes patient screening for DiaPrevent Phase III study

Diamyd Medical has completed the screening of patients for the US Phase III study, DiaPrevent, ending the recruitment campaign. More than 310 recently diagnosed type 1 diabetes patients between 10 and 20 years of age have already been enrolled in the study and have received their first injection of the antigen-based therapy Diamyd® or placebo.

10 Nov 2010

Only one-third of young women complete HPV regimen

Despite strong evidence of its effectiveness, few of the young women who are eligible for the human papillomavirus (HPV) vaccine take it, according to research presented at the Ninth Annual AACR Frontiers in Cancer Prevention Research Conference, held Nov. 7-10.

10 Nov 2010

Albert Einstein researcher receives Medal of Honor from American Cancer Society

Albert Einstein College of Medicine of Yeshiva University researcher Jeffrey Pollard, Ph.D., has received the prestigious Medal of Honor in Basic Science from the American Cancer Society (ACS) in recognition of his research into the critical role the tumor microenvironment plays in modulating cancer behavior, specifically the role that members of the innate immune cells called macrophages play both in normal development and in promoting tumor progression. These macrophages could hold the key to more targeted cancer treatments.

10 Nov 2010

Enrollment complete in Nabi's second NicVAX Phase III clinical trial for nicotine addiction

Nabi Biopharmaceuticals announced today that it has completed enrollment in the second Phase III clinical trial of NicVAX® (Nicotine Conjugate Vaccine), the company's innovative and proprietary investigational candidate vaccine being developed to treat nicotine addiction and prevent smoking relapse.

10 Nov 2010

Senior Scientific receives QTDP grants for cancer detection and treatment

Manhattan Scientifics, Inc. (OTCBB: MHTX) announced that Senior Scientific LLC is the recipient of four grants totaling $702,899 awarded by the Qualifying Therapeutic Discovery Grant Program.

10 Nov 2010

FlexStent Femoropopliteal SE Stent System FIM study results presented at VIVA conference

Final first-in-man (FIM) clinical results on the use of the FlexStent® Femoropopliteal SE Stent System were presented recently at the VIVA conference in Las Vegas by Dr. Andrew Holden of Auckland City Hospital. The clinical results originated from Flexible Stenting Solutions, Inc.'s (FSS) FIM study conducted in New Zealand by Principle Investigator Dr. Andrew Holden, and FSS's supplementary study conducted in Germany by Principle Investigator Dr. Dierk Scheinert of University of Leipzig - Heart Center.

10 Nov 2010

Medical Condition News

Researchers estimate increasing trend of hyperuricemia among adults, senior citizens

Families fight to care for disabled kids at home after they reach the age of 21

ECRI Institute introduces CT Radiation Dose Safety Review service to reduce risk of excessive radiation

Synageva's SBC-102 enzyme replacement therapy for LAL deficiency granted European orphan product designation

Neogenix awarded $488,958.50 grant under QTDP program

Clot-busting drug remains the most beneficial emergency treatment for strokes

Special Surgery investigators to present future of clinical care at ACR annual meeting

New robotic surgery technique for kidney cancer reduces organ damage

BioInvent receives FDA IND clearance for BI-204 Phase II trial in cardiovascular disease

Immunologix partners with Genscript to develop human antibody therapeutics

Restylane boosts people's first impression

Adolescent obesity associated with risk of severe obesity in adulthood

TONIX Pharmaceuticals announces Phase 2a study results of cyclobenzaprine in Fibromyalgia Syndrome

Silence Therapeutics' Atu027 RNAi drug prevents pulmonary metastasis formation

Diamyd completes patient screening for DiaPrevent Phase III study

Only one-third of young women complete HPV regimen

Albert Einstein researcher receives Medal of Honor from American Cancer Society

Enrollment complete in Nabi's second NicVAX Phase III clinical trial for nicotine addiction

Senior Scientific receives QTDP grants for cancer detection and treatment

FlexStent Femoropopliteal SE Stent System FIM study results presented at VIVA conference

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News